These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 25074636)

  • 1. Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder.
    Savitz J; Drevets WC; Smith CM; Victor TA; Wurfel BE; Bellgowan PS; Bodurka J; Teague TK; Dantzer R
    Neuropsychopharmacology; 2015 Jan; 40(2):463-71. PubMed ID: 25074636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder.
    Savitz J; Dantzer R; Wurfel BE; Victor TA; Ford BN; Bodurka J; Bellgowan PS; Teague TK; Drevets WC
    Psychoneuroendocrinology; 2015 Feb; 52():200-11. PubMed ID: 25486577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.
    Meier TB; Drevets WC; Wurfel BE; Ford BN; Morris HM; Victor TA; Bodurka J; Teague TK; Dantzer R; Savitz J
    Brain Behav Immun; 2016 Mar; 53():39-48. PubMed ID: 26546831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kynurenine pathway metabolites are associated with hippocampal activity during autobiographical memory recall in patients with depression.
    Young KD; Drevets WC; Dantzer R; Teague TK; Bodurka J; Savitz J
    Brain Behav Immun; 2016 Aug; 56():335-42. PubMed ID: 27091600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the kynurenine pathway is associated with striatal volume in major depressive disorder.
    Savitz J; Dantzer R; Meier TB; Wurfel BE; Victor TA; McIntosh SA; Ford BN; Morris HM; Bodurka J; Teague TK; Drevets WC
    Psychoneuroendocrinology; 2015 Dec; 62():54-8. PubMed ID: 26232650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes.
    Doolin K; Allers KA; Pleiner S; Liesener A; Farrell C; Tozzi L; O'Hanlon E; Roddy D; Frodl T; Harkin A; O'Keane V
    Psychoneuroendocrinology; 2018 Sep; 95():8-17. PubMed ID: 29787958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder.
    Savitz J; Drevets WC; Wurfel BE; Ford BN; Bellgowan PS; Victor TA; Bodurka J; Teague TK; Dantzer R
    Brain Behav Immun; 2015 May; 46():55-9. PubMed ID: 25686798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kynurenic acid is reduced in females and oral contraceptive users: Implications for depression.
    Meier TB; Drevets WC; Teague TK; Wurfel BE; Mueller SC; Bodurka J; Dantzer R; Savitz J
    Brain Behav Immun; 2018 Jan; 67():59-64. PubMed ID: 28867283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-Reactive protein and the kynurenic acid to quinolinic acid ratio are independently associated with white matter integrity in major depressive disorder.
    Zheng H; Teague TK; Yeh FC; Burrows K; Figueroa-Hall LK; Aupperle RL; Khalsa SS; Paulus MP; Savitz J
    Brain Behav Immun; 2022 Oct; 105():180-189. PubMed ID: 35853557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-time fMRI neurofeedback amygdala training may influence kynurenine pathway metabolism in major depressive disorder.
    Tsuchiyagaito A; Smith JL; El-Sabbagh N; Zotev V; Misaki M; Al Zoubi O; Kent Teague T; Paulus MP; Bodurka J; Savitz J
    Neuroimage Clin; 2021; 29():102559. PubMed ID: 33516062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-sectional relationship between kynurenine pathway metabolites and cognitive function in major depressive disorder.
    Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Ning Y
    Psychoneuroendocrinology; 2019 Mar; 101():72-79. PubMed ID: 30419374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral and central kynurenine pathway abnormalities in major depression.
    Paul ER; Schwieler L; Erhardt S; Boda S; Trepci A; Kämpe R; Asratian A; Holm L; Yngve A; Dantzer R; Heilig M; Hamilton JP; Samuelsson M
    Brain Behav Immun; 2022 Mar; 101():136-145. PubMed ID: 34999196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ongoing episode of major depressive disorder is not associated with elevated plasma levels of kynurenine pathway markers.
    Dahl J; Andreassen OA; Verkerk R; Malt UF; Sandvik L; Brundin L; Ormstad H
    Psychoneuroendocrinology; 2015 Jun; 56():12-22. PubMed ID: 25770856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot resting-state functional connectivity study of the kynurenine pathway in adolescents with depression and healthy controls.
    DeWitt SJ; Bradley KA; Lin N; Yu C; Gabbay V
    J Affect Disord; 2018 Feb; 227():752-758. PubMed ID: 29254065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of electroconvulsive therapy (ECT) on serum tryptophan metabolites.
    Aarsland TI; Leskauskaite I; Midttun Ø; Ulvik A; Ueland PM; Oltedal L; Erchinger VJ; Oedegaard KJ; Haavik J; Kessler U
    Brain Stimul; 2019; 12(5):1135-1142. PubMed ID: 31176607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum kynurenic acid is reduced in affective psychosis.
    Wurfel BE; Drevets WC; Bliss SA; McMillin JR; Suzuki H; Ford BN; Morris HM; Teague TK; Dantzer R; Savitz JB
    Transl Psychiatry; 2017 May; 7(5):e1115. PubMed ID: 28463241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does escitalopram reduce neurotoxicity in major depression?
    Halaris A; Myint AM; Savant V; Meresh E; Lim E; Guillemin G; Hoppensteadt D; Fareed J; Sinacore J
    J Psychiatr Res; 2015; 66-67():118-26. PubMed ID: 26009299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sleep disturbance and kynurenine metabolism in depression.
    Cho HJ; Savitz J; Dantzer R; Teague TK; Drevets WC; Irwin MR
    J Psychosom Res; 2017 Aug; 99():1-7. PubMed ID: 28712413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies.
    Marx W; McGuinness AJ; Rocks T; Ruusunen A; Cleminson J; Walker AJ; Gomes-da-Costa S; Lane M; Sanches M; Diaz AP; Tseng PT; Lin PY; Berk M; Clarke G; O'Neil A; Jacka F; Stubbs B; Carvalho AF; Quevedo J; Soares JC; Fernandes BS
    Mol Psychiatry; 2021 Aug; 26(8):4158-4178. PubMed ID: 33230205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tryptophan, kynurenine, and kynurenine metabolites: Relationship to lifetime aggression and inflammatory markers in human subjects.
    Coccaro EF; Lee R; Fanning JR; Fuchs D; Goiny M; Erhardt S; Christensen K; Brundin L; Coussons-Read M
    Psychoneuroendocrinology; 2016 Sep; 71():189-96. PubMed ID: 27318828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.